Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
81% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ANIK: No Debt )
ANIK' s 10-Year Cash to Debt Range
Min: 1.7   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ANIK's Equity to Asset is ranked higher than
89% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ANIK: 0.87 )
ANIK' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.92
Current: 0.87

0.51
0.92
Interest Coverage 256.75
ANIK's Interest Coverage is ranked higher than
61% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: 256.75 )
ANIK' s 10-Year Interest Coverage Range
Min: 38.66   Max: 9999.99
Current: 256.75

38.66
9999.99
F-Score: 7
Z-Score: 18.94
M-Score: -2.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 43.43
ANIK's Operating margin (%) is ranked higher than
98% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ANIK: 43.43 )
ANIK' s 10-Year Operating margin (%) Range
Min: -225   Max: 43.43
Current: 43.43

-225
43.43
Net-margin (%) 27.40
ANIK's Net-margin (%) is ranked higher than
95% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ANIK: 27.40 )
ANIK' s 10-Year Net-margin (%) Range
Min: -225   Max: 42.28
Current: 27.4

-225
42.28
ROE (%) 15.17
ANIK's ROE (%) is ranked higher than
93% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ANIK: 15.17 )
ANIK' s 10-Year ROE (%) Range
Min: -54   Max: 36.85
Current: 15.17

-54
36.85
ROA (%) 13.19
ANIK's ROA (%) is ranked higher than
95% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ANIK: 13.19 )
ANIK' s 10-Year ROA (%) Range
Min: -39.13   Max: 18.79
Current: 13.19

-39.13
18.79
ROC (Joel Greenblatt) (%) 59.38
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ANIK: 59.38 )
ANIK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -112.5   Max: 217.47
Current: 59.38

-112.5
217.47
Revenue Growth (%) 7.50
ANIK's Revenue Growth (%) is ranked higher than
81% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ANIK: 7.50 )
ANIK' s 10-Year Revenue Growth (%) Range
Min: -4.5   Max: 75.4
Current: 7.5

-4.5
75.4
EBITDA Growth (%) 46.60
ANIK's EBITDA Growth (%) is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ANIK: 46.60 )
ANIK' s 10-Year EBITDA Growth (%) Range
Min: -65.1   Max: 95.7
Current: 46.6

-65.1
95.7
EPS Growth (%) 63.20
ANIK's EPS Growth (%) is ranked higher than
98% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ANIK: 63.20 )
ANIK' s 10-Year EPS Growth (%) Range
Min: -64.3   Max: 72.4
Current: 63.2

-64.3
72.4
» ANIK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ANIK Guru Trades in Q1 2013

Jim Simons 364,800 sh (-7.73%)
» More
Q2 2013

ANIK Guru Trades in Q2 2013

Chuck Royce 1,900 sh (New)
Jim Simons 370,703 sh (+1.62%)
» More
Q3 2013

ANIK Guru Trades in Q3 2013

Joel Greenblatt 68,532 sh (New)
Jim Simons 402,100 sh (+8.47%)
Chuck Royce 1,900 sh (unchged)
» More
Q4 2013

ANIK Guru Trades in Q4 2013

Joel Greenblatt Sold Out
Jim Simons 396,800 sh (-1.32%)
Chuck Royce 1,600 sh (-15.79%)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.05%$23.64 - $38.09 $ 39.2327%0
Joel Greenblatt 2013-09-30 New Buy0.05%$17.74 - $27.28 $ 39.2374%68532
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.80
ANIK's P/E(ttm) is ranked higher than
67% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ANIK: 28.80 )
ANIK' s 10-Year P/E(ttm) Range
Min: 8.66   Max: 158.59
Current: 28.8

8.66
158.59
P/B 4.00
ANIK's P/B is ranked higher than
68% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ANIK: 4.00 )
ANIK' s 10-Year P/B Range
Min: 0.58   Max: 6.39
Current: 4

0.58
6.39
P/S 7.80
ANIK's P/S is ranked higher than
62% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ANIK: 7.80 )
ANIK' s 10-Year P/S Range
Min: 1   Max: 9.2
Current: 7.8

1
9.2
PFCF 23.78
ANIK's PFCF is ranked higher than
71% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ANIK: 23.78 )
ANIK' s 10-Year PFCF Range
Min: 3.71   Max: 1445
Current: 23.78

3.71
1445
EV-to-EBIT 15.29
ANIK's EV-to-EBIT is ranked higher than
68% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ANIK: 15.29 )
ANIK' s 10-Year EV-to-EBIT Range
Min: 1.8   Max: 190.1
Current: 15.29

1.8
190.1
PEG 0.66
ANIK's PEG is ranked higher than
87% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ANIK: 0.66 )
ANIK' s 10-Year PEG Range
Min: 0.38   Max: 10.83
Current: 0.66

0.38
10.83
Shiller P/E 60.78
ANIK's Shiller P/E is ranked lower than
52% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. ANIK: 60.78 )
ANIK' s 10-Year Shiller P/E Range
Min: 6.1   Max: 178.13
Current: 60.78

6.1
178.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.66
ANIK's Price/Net Cash is ranked lower than
53% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. ANIK: 12.66 )
ANIK' s 10-Year Price/Net Cash Range
Min: 0.48   Max: 23.44
Current: 12.66

0.48
23.44
Price/Net Current Asset Value 8.68
ANIK's Price/Net Current Asset Value is ranked higher than
58% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ANIK: 8.68 )
ANIK' s 10-Year Price/Net Current Asset Value Range
Min: 0.39   Max: 9.33
Current: 8.68

0.39
9.33
Price/Tangible Book 5.06
ANIK's Price/Tangible Book is ranked higher than
65% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ANIK: 5.06 )
ANIK' s 10-Year Price/Tangible Book Range
Min: 0.29   Max: 7.65
Current: 5.06

0.29
7.65
Price/DCF (Projected) 3.21
ANIK's Price/DCF (Projected) is ranked higher than
59% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ANIK: 3.21 )
ANIK' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 20.72
Current: 3.21

0.53
20.72
Price/Median PS Value 2.32
ANIK's Price/Median PS Value is ranked lower than
62% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ANIK: 2.32 )
ANIK' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.26
Current: 2.32

0.15
2.26
Price/Peter Lynch Fair Value 1.15
ANIK's Price/Peter Lynch Fair Value is ranked higher than
86% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ANIK: 1.15 )
ANIK' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.37   Max: 19.53
Current: 1.15

0.37
19.53
Price/Graham Number 2.44
ANIK's Price/Graham Number is ranked higher than
67% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ANIK: 2.44 )
ANIK' s 10-Year Price/Graham Number Range
Min: 0.5   Max: 5.32
Current: 2.44

0.5
5.32
Earnings Yield (Greenblatt) 6.50
ANIK's Earnings Yield (Greenblatt) is ranked higher than
72% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ANIK: 6.50 )
ANIK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 56.4
Current: 6.5

0.5
56.4
Forward Rate of Return (Yacktman) 43.72
ANIK's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ANIK: 43.72 )
ANIK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.7   Max: 50.9
Current: 43.72

-10.7
50.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AKP.Germany
Anika Therapeutics, Inc., was incorporated under the laws of the state of Massachusetts in 1992. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid ("HA"), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. Anika Therapeutics, Inc.'s wholly-owned subsidiary, Anika Therapeutics S.r.l., has over 20 products currently commercialized, mainly in Europe. These products are also all made from hyaluronic acid, based on two technologies: "HYAFF", which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Ophthalmic, Surgical, and Veterinary. Its orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its dermal products consist of advanced wound care products, a field relatively new to the Company as a result of the acquisition of Anika S.r.l., and aesthetic dermal fillers. Anika S.r.l. offers over seven products for the treatment of skin wounds ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents, advanced therapies and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. HYVISC is a high molecular weight injectable HA product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. HYVISC has viscoelastic properties that lubricate and protect the tissues in horse joints. It competes with many companies, including, among others, large pharmaceutical firms and specialized medical products companies across all of its product lines. It also competes with academic institutions, governmental agencies and other rese

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide